Mixed Dyslipidemia Among Patients Using Lipid-Lowering Therapy in French General Practice: An Observational Study

Clinical Therapeutics

Volumn 29, Issue 8, 2007, Pages 1671-1681

  Van Ganse, Eric ^a   Laforest, Laurent ^a   Burke, Thomas ^b   Phatak, Hemant ^b   Souchet, Thierry ^b  

^a HOSPICES CIVILS DE LYON   (France)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

cholesterol; dyslipidemia; HDL C; high density lipoprotein cholesterol; LDL C; low density lipoprotein; primary care; TGs; triglycerides

Indexed keywords

ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; FRANCE; GENERAL PRACTICE; GENERAL PRACTITIONER; HUMAN; ISCHEMIC HEART DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PREVALENCE; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DATABASES AS TOPIC; DIABETES MELLITUS; DYSLIPIDEMIAS; FAMILY PRACTICE; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TRIGLYCERIDES;

EID: 34848872209     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.08.003     Document Type: Article

References (40)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (45). Lancet 344 (1994) 1383-1389
2. Shepherd J., Cobbe S., Ford I., et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N EnglJ Med 333 (1995) 1301-1307
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial. Lancet 360 (2002) 7-22
4. Baigent C., Keech A., Kearney P., et al., for the Cholesterol Treatment Trialists' (CTi-) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data From 90,056 participants in 14 randomised trials ofstatins [published correction appears in Lancet. 2005;366:1358]. Lancet 366 (2005) 1267-1278
5. Stone N., Bilek S., and Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III update: Adjustments and options. Am J Cardiol 96 (2005) 53E-59E
6. Gordon D., Probstfield J., Garrison R., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15
7. Grundy S., Cleeman J., Merz C., et al., for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coil Cardiol 44 (2004) 720-732
8. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
9. Robins S. Targeting low high-density lipoprotein cholesterol for therapy: Lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial. Am J Cardiol 88 (2001) 19N-23N
10. Wilhelmsen L., Pyorala K., Wedel H., et al. Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. Eur Heart J 22 (2001) 1119-1127
11. Agence Française de Sécurité Sanitaire des Produits de Santé. Therapeutic management of dyslipidemic patients: Guidelines [in French]. (2005), French Health Products Safety Agency (AFSSAPS), Saint Denis, France. http://www.afssaps.sante.fr/pdf/5/rbp/dysreco.pdf Accessed November 20, 2006
12. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European guide-lines on cardiovascular disease prevention in clinical practice: Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prey Rehabil 10 (2003) S1-S10
13. Criqui M., Heiss G., Cohn R., et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 328 (1993) 1220-1225
14. Avins A., and Neuhaus J. Do triglycerides provide meaningful information about heart disease risk?. Arch Intern Med 160 (2000) 1937-1944
15. Menotti A., Scanga M., and Morisi G. Serum triglycerides in the prediction of coronary artery disease (an Italian experience). Am J Cardiol 73 (1994) 29-32
16. Jeppesen J., Hein H., Suadicani P., and Gyntelberg F. Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study [published correction appears in Circulation. 1998; 97:1995]. Circulation 97 (1998) 1029-1036
17. Hokanson J., and Austin M. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk 3 (1996) 213-219
18. Bainton D., Miller N., Bolton C., et al. Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men. The Caerphilly and Speed-well Collaborative Heart Disease Studies. Br Heart J 68 (1992) 60-66
19. Stampfer M., Krauss R., Ma J., et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 276 (1996) 882-888
20. Iso H., Naito Y., Sato S., et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol 153 (2001) 490-499
21. Psaty B., Anderson M., Kronmal R., et al. The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: The Cardiovascular Health Study. J Am Geriatr Soc 52 (2004) 1639-1647
22. Haim M., Benderly M., Brunner D., et al. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: The Bezafibrate Infarction Prevention (BIP) Registry. Circulation 100 (1999) 475-482
23. Van Ganse E. Use of computerized data in pharmacoepidemiology [in French]. Therapie 55 (2000) 123-126
24. Van Ganse E., Souchet T., Laforest L., et al. Ineffectiveness of lipid-lowering therapy in primary care. Br J Clin Pharmacol 59 (2005) 456-463
25. Wilson P., D'Agostino R., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
26. Hosmer D., and Lemeshow S. Applied Logistic Regression (1989), John Wiley & Sons, New York, NY
27. Kleinbaum D., and Klein M. Logistic Regression: A SelfLearning Text. 2nd ed. (2002), Springer, New York, NY
28. Persell S., Lloyd-Jones D., and Baker D. Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia. J Gen Intern Med 21 (2006) 171-176
29. Ferrieres J., Ruidavets J., Perret B., et al. Prevalence ofdyslipidaemias in a representative sample of the French population [in French]. Arch Mal Coeur Vaiss 98 (2005) 127-132
30. Primatesta P., and Poulter N. Lipid concentrations and the use of lipid lowering drugs: Evidence from a national cross sectional survey. BMJ 321 (2000) 1322-1325
31. Carroll M., Lacher D., Sorlie P., et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 294 (2005) 1773-1781
32. Robins S., Collins D., Wittes J., et al., for the VA-H IT Study Group (Veterans Affairs High-Density Lipoprotein Intervention Trial). Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-H IT: A randomized controlled trial. JAMA 285 (2001) 1585-1591
33. for the European Consensus Panel on HDL-C. Chapman M., Assmann G., Fruchart J., et al. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: The role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 20 (2004) 1253-1268
34. Pogach L., Brietzke S., Cowan Jr. C., et al. Development of evidence-based clinical practice guidelines for diabetes: The Department of Veterans Affairs/Department of Defense guide-lines initiative. Diabetes Care 27 Suppl 2 (2004) B82-B89
35. Jeppesen J., Hein H., Suadicani P., and Gyntelberg F. Relation of high TG-Iow HDL cholesterol and LDL cholesterol to the incidence ofischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol 17 (1997) 1114-1120
36. Connelly P., Petrasovits A., Stachenko S., et al., for the Canadian Heart Health Surveys Research Group. Prevalence of high plasma triglyceride combined with low HDL-C levels and its association with smoking, hypertension, obesity, diabetes, sedentariness and LDL-C levels in the Canadian population. CanJ Cardiol 15 (1999) 428-433
37. Verges B. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab 31 (2005) 429-439
38. Bruckert E., Baccara-Dinet M., McCoy F., and Chapman J. High prevalence of low HDUcholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin 21 (2005) 1927-1934
39. Hobbs R., and Hoes A. Effective management ofdyslipidaemia among patients with cardiovascular risk: Updated recommendations on identification and follow-up. EurJ Gen Pract 11 (2005) 68-75
40. Van Ganse E., Laforest L., Alemao E., et al. Lipid-modifying therapy and attainment of cholesterol goals in Europe: The Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 21 (2005) 1389-1399